Phase I-IIA Study of GLS-5300 Vaccine for Mers-Cov: Preliminary Results Demonstrate B and T Cell Immune Response Elicited in Lower-Dose 2-and 3-Vaccination Intradermally Administered Regimens
MOLECULAR THERAPY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要